These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 34357135)

  • 1. Plitidepsin: Mechanisms and Clinical Profile of a Promising Antiviral Agent against COVID-19.
    Papapanou M; Papoutsi E; Giannakas T; Katsaounou P
    J Pers Med; 2021 Jul; 11(7):. PubMed ID: 34357135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.
    White KM; Rosales R; Yildiz S; Kehrer T; Miorin L; Moreno E; Jangra S; Uccellini MB; Rathnasinghe R; Coughlan L; Martinez-Romero C; Batra J; Rojc A; Bouhaddou M; Fabius JM; Obernier K; Dejosez M; Guillén MJ; Losada A; Avilés P; Schotsaert M; Zwaka T; Vignuzzi M; Shokat KM; Krogan NJ; García-Sastre A
    Science; 2021 Feb; 371(6532):926-931. PubMed ID: 33495306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plitidepsin: a Repurposed Drug for the Treatment of COVID-19.
    Martinez MA
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33558296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis.
    Sachse M; Tenorio R; Fernández de Castro I; Muñoz-Basagoiti J; Perez-Zsolt D; Raïch-Regué D; Rodon J; Losada A; Avilés P; Cuevas C; Paredes R; Segalés J; Clotet B; Vergara-Alert J; Izquierdo-Useros N; Risco C
    Antiviral Res; 2022 Apr; 200():105270. PubMed ID: 35231500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant.
    Reuschl AK; Thorne LG; Zuliani-Alvarez L; Bouhaddou M; Obernier K; Hiatt J; Soucheray M; Turner J; Fabius JM; Nguyen GT; Swaney DL; Rosales R; White KM; Avilés P; Kirby IT; Melnyk JE; Shi Y; Zhang Z; Shokat KM; García-Sastre A; Jolly C; Towers GJ; Krogan NJ
    bioRxiv; 2021 Feb; ():. PubMed ID: 33501437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remdesivir for the treatment of COVID-19.
    Ansems K; Grundeis F; Dahms K; Mikolajewska A; Thieme V; Piechotta V; Metzendorf MI; Stegemann M; Benstoem C; Fichtner F
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014962. PubMed ID: 34350582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hunting the main protease of SARS-CoV-2 by plitidepsin: Molecular docking and temperature-dependent molecular dynamics simulations.
    Vishvakarma VK; Singh MB; Jain P; Kumari K; Singh P
    Amino Acids; 2022 Feb; 54(2):205-213. PubMed ID: 34807314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational Prediction of the Potential Target of SARS-CoV-2 Inhibitor Plitidepsin via Molecular Docking, Dynamic Simulations and MM-PBSA Calculations.
    El Hassab MA; Hemeda LR; Elsayed ZM; Al-Rashood ST; Abdel-Hamid Amin MK; Abdel-Aziz HA; Eldehna WM
    Chem Biodivers; 2022 Feb; 19(2):e202100719. PubMed ID: 34813168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes and clinical characteristics of the compassionate use of plitidepsin in COVID-19 patients with solid tumours, haematological malignancies or anti-CD20 antibody treatment.
    Aguareles J; Villares Fernández P; Forné C; Martí-Ballesteros EM; Pradillo Fernández V; Sotres-Fernandez G; de la Fuente-Burguera A; Navarro-San Francisco C; Buzón-Martín LM; García-Delangue T; Aiello FT; Carnevali-Ruiz D; Lloris R; Luepke-Estefan XE; López-Martín JA; Jimeno JM; García-Casas A; Guisado-Vasco P
    Infect Dis (Lond); 2024 Jul; 56(7):575-580. PubMed ID: 38743059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Plitidepsin, an inhibitor of the cell elongation factor eEF1a, and molnupiravir an analogue of the ribonucleoside cytidine, two new chemical compounds with intense activity against SARS-CoV-2].
    Reina J
    Rev Esp Quimioter; 2021 Oct; 34(5):402-407. PubMed ID: 33902254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes and clinical characteristics of the compassionate use of plitidepsin for immunocompromised adult patients with COVID-19.
    Aguareles J; Fernández PV; Carralón-González MM; Izquierdo CF; Martí-Ballesteros EM; Fernández VP; Sotres-Fernandez G; García-Delangue T; LaPetra RGV; Sánchez-Manzano MD; Gutiérrez C; García-Coca M; Carnevali-Ruiz D; Barrena-Puertas R; Luque-Pinilla JM; Lloris R; Luepke-Estefan XE; López-Martín JA; Jimeno JM; Guisado-Vasco P
    Int J Infect Dis; 2023 Oct; 135():12-17. PubMed ID: 37481109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization.
    Varona JF; Landete P; Lopez-Martin JA; Estrada V; Paredes R; Guisado-Vasco P; de Orueta LF; Torralba M; Fortún J; Vates R; Barberán J; Clotet B; Ancochea J; Carnevali D; Cabello N; Porras L; Gijón P; Monereo A; Abad D; Zúñiga S; Sola I; Rodon J; Izquierdo-Useros N; Fudio S; Pontes MJ; de Rivas B; Girón de Velasco P; Sopesén B; Nieto A; Gómez J; Avilés P; Lubomirov R; White KM; Rosales R; Yildiz S; Reuschl AK; Thorne LG; Jolly C; Towers GJ; Zuliani-Alvarez L; Bouhaddou M; Obernier K; Enjuanes L; Fernández-Sousa JM; ; Krogan NJ; Jimeno JM; García-Sastre A
    medRxiv; 2021 May; ():. PubMed ID: 34075384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.
    Varona JF; Landete P; Lopez-Martin JA; Estrada V; Paredes R; Guisado-Vasco P; Fernandez de Orueta L; Torralba M; Fortun J; Vates R; Barberan J; Clotet B; Ancochea J; Carnevali D; Cabello N; Porras L; Gijon P; Monereo A; Abad D; Zuñiga S; Sola I; Rodon J; Vergara-Alert J; Izquierdo-Useros N; Fudio S; Pontes MJ; de Rivas B; Giron de Velasco P; Nieto A; Gomez J; Aviles P; Lubomirov R; Belgrano A; Sopesen B; White KM; Rosales R; Yildiz S; Reuschl AK; Thorne LG; Jolly C; Towers GJ; Zuliani-Alvarez L; Bouhaddou M; Obernier K; McGovern BL; Rodriguez ML; Enjuanes L; Fernandez-Sousa JM; Krogan NJ; Jimeno JM; Garcia-Sastre A
    Life Sci Alliance; 2022 Apr; 5(4):. PubMed ID: 35012962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.
    Olagunju A; Fowotade A; Olagunoye A; Ojo TO; Adefuye BO; Fagbamigbe AF; Adebiyi AO; Olagunju OI; Ladipo OT; Akinloye A; Adeagbo BA; Onayade A; Bolaji OO; Happi C; Rannard S; Owen A
    Trials; 2021 Jan; 22(1):3. PubMed ID: 33397457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plitidepsin: design, development, and potential place in therapy.
    Alonso-Álvarez S; Pardal E; Sánchez-Nieto D; Navarro M; Caballero MD; Mateos MV; Martín A
    Drug Des Devel Ther; 2017; 11():253-264. PubMed ID: 28176904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.